Euclid Announces Sales Team Expansion as the Company Leads Efforts in Myopia Management Across the Globe

Euclid Systems Corporation, a global leader in proactive myopia management and manufacturer of advanced orthokeratology lens products, is pleased to announce the expansion of the US sales team with the addition of Karen Slaughter. She will be responsible for account management for independent eye care professionals in the western region of the United States.

“Karen brings over twenty years of experience in the contact lens industry, along with extensive knowledge of the many facets of specialty eye care, including orthokeratology,”

stated David Bland, Euclid’s vice president of sales.

“Her enthusiasm and expertise will have a significant positive impact for eye care professionals in reaching their practice goals. We are thrilled to have her join the Euclid team.”

Prior to joining Euclid, Karen excelled in the senior sales positions she held with Bausch + Lomb Specialty Vision Products, Ocular Sciences, and CooperVision.

At Euclid, Karen will work closely with practitioners to help them expand their myopia management practices through orthokeratology, specifically with the Euclid Emerald^TM family of products.

The continuing growth of the Euclid team with its investment in knowledgeable and experienced business professionals, along with the company’s commitment to innovation, evolved resources, and targeted programs, support its mission to improve the lives of patients globally by providing the best technology and highest quality solutions for myopia management.

About Euclid Systems Corporation

Euclid Systems Corporation is a world leader in myopia management and manufacturer of advanced orthokeratology lens products. With headquarters in Virginia, USA, and offices in Shanghai and Beijing, China, Euclid is leading the efforts in myopia management across the globe.

Multiple clinical studies worldwide by prestigious independent researchers have proven the effectiveness of orthokeratology, and specifically the Euclid Emerald^TM lens, on slowing the progression of myopia. The Euclid Ortho-K treatment has a unique, empirically fit lens design with no trial lenses required. Manufactured in the U. S., the Euclid Emerald lens design has received FDA approval in the U.S., CE mark for Europe, as well as regulatory approvals from numerous countries around the world. To learn more, visit www.euclidlenses.com.